Transcription of ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
{{id}} {{{paragraph}}}
Example: barber
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
1 ANNEX ISUMMARY OF PRODUCT CHARACTERISTICS2 This medicinal PRODUCT is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section for how to report adverse OF THEMEDICINAL PRODUCTRINVOQ15 mg prolonged-release tabletsRINVOQ 30 mg prolonged-release tabletsRINVOQ 45 mg prolonged-release AND QUANTITATIVE COMPOSITIONRINVOQ 15 mg prolonged-release tabletsEach prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 15mg of 30 mg prolonged-release tabletsEach prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 30mg of 45mg prolonged-release tabletsEach prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 45 mg of the full list of excipients.
RINVOQ 30 mg prolonged-release tablets . Each prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 30 mg of upadacitinib. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM. Prolonged-release tablet . RINVOQ 15 mg prolonged-release tablet s . Purple 14 x 8 mm, oblong biconvex prolonged- release tablets ...
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: